Belchetz P E
Department of Medicine, University of Liverpool, UK.
Postgrad Med J. 1987 Apr;63(738):241-4. doi: 10.1136/pgmj.63.738.241.
The results of testing growth hormone (GH) reserve using human pancreatic growth hormone-releasing factor 1-44 amide (hp GRF 1-44 amide) have been compared with the GH responses in a variety of other dynamic tests in seven acromegalic patients. The GH release following hp GRF 1-44 amide correlated with the GH suppression following bromocriptine, but showed an inverse correlation with the GH release following stress tests (insulin-induced hypoglycaemia/glucagon). There was no correlation between the GH responses in these three tests and any of the other tests: TRH, GnRH and glucose. A hypothesis is proposed to explain these findings on the basis of varying degrees of GH secretion from adenomatous and normal pituitary somatotrophs in acromegaly.
在7例肢端肥大症患者中,已将使用人胰腺生长激素释放因子1 - 44酰胺(hp GRF 1 - 44酰胺)检测生长激素(GH)储备的结果与多种其他动态试验中的GH反应进行了比较。hp GRF 1 - 44酰胺后的GH释放与溴隐亭后的GH抑制相关,但与应激试验(胰岛素诱导的低血糖/胰高血糖素)后的GH释放呈负相关。这三项试验中的GH反应与其他任何试验(促甲状腺激素释放激素、促性腺激素释放激素和葡萄糖)之间均无相关性。提出了一个假说,以根据肢端肥大症中腺瘤性和正常垂体生长激素细胞不同程度的GH分泌来解释这些发现。